Clinical Trial Update: Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody, for bullous pemphigoid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Avdoralimab (IPH5401)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Bullous Pemphigoid | Phase 2 | Status: COMPLETED